Desk Report
Oniket Desk
Dr. Md. Abu Zafor Sadek’s recent article (published in the Daily Star) offers a concise and industry oriented account of the reform agenda confronting Bangladesh’s pharmaceutical sector at a pivotal moment. Written with evident insider knowledge, the piece covers a range of operational and regulatory concerns with clarity and directness. It is a useful contribution to the policy discourse. However, as a comprehensive reform blueprint, it carries several significant gaps that limit its analytical depth and prescriptive value.
Strengths of the Article
Sadek correctly identifies the structural headwinds that have slowed the sector since the Covid-19 pandemic, covering raw material shortages, currency depreciation, freight cost escalation, and pricing rigidity. The article frames them coherently within the broader growth trajectory of an industry that sustained 15 to 25 percent annual expansion from the mid-80s to the pre pandemic period. The article’s call for digitalized drug registration, evidence based pricing mechanisms, and a coordinated one stop import clearance system reflects an understanding of where bureaucratic friction most damages sector efficiency.
The discussion of the API Industrial Park in Gazaria as an underutilized strategic asset, and the urgent warning about post-LDC TRIPS obligations, are the article’s most valuable contributions. These are issues that rarely receive the public attention they deserve, and Sadek raises them with appropriate urgency.
However, our desk identified the following gaps in the article. To read the main article, please visit https://www.thedailystar.net/business/news/what-rapid-reforms-the-pharma-sector-needs-4169166.
The Absence of an R&D and Innovation Agenda
The most consequential omission in Sadek’s article is any substantive engagement with research and development. The entire reform agenda is structured around optimising the existing generic manufacturing model that includes faster registration, better pricing, smoother imports. Yet Bangladesh’s long-term pharmaceutical competitiveness cannot rest on generics alone, particularly as post-LDC patent protections begin to apply.
The article acknowledges that “innovation capacity for new molecules remains limited” but offers no pathway to change this. A stronger version of this article would have recommended dedicated R&D tax incentives, university-industry research consortia, and public co-investment in biologic and biosimilar manufacturing capacity, areas where global demand is growing rapidly and where Bangladesh has the human capital foundation to compete, if directed appropriately.
Drug Quality, Counterfeiting, and Pharmacovigilance
Sadek’s article is silent on the significant challenge of substandard and counterfeit medicines circulating in Bangladesh’s domestic market. This problem undermines public trust in locally manufactured drugs and creates regulatory reputational risk for export markets. No mention is made of pharmacovigilance infrastructure, post market surveillance systems, or the strengthening of the Directorate General of Drug Administration’s enforcement capacity. A reform agenda that prioritises speed of registration without equally prioritising post-approval quality assurance is structurally incomplete.
Workforce Development and Skilled Talent
The article contains no discussion of human capital. Pharmaceutical manufacturing at an internationally competitive level (particularly in biologics, sterile injectables, and API synthesis) requires a highly specialised workforce. Bangladesh currently lacks enough qualified pharmaceutical chemists, regulatory affairs professionals, and quality assurance engineers. A reform agenda that overlooks training, curriculum alignment with industry needs, and retention of skilled professionals is likely to encounter execution barriers regardless of how well the regulatory environment is reformed.
Environmental Compliance and Sustainability
Pharmaceutical manufacturing generates significant chemical and biological waste. The article does not address environmental compliance at all. This remains a notable omission given that several Bangladeshi manufacturers have faced scrutiny from international regulators over effluent management. As Bangladesh seeks to expand its export footprint in regulated markets such as the European Union and the United States, environmental standards are not peripheral concerns; they are market access prerequisites.
Equity and Access Dimensions
Sadek’s article frames reform primarily from the industry’s perspective. The patient and public health perspective of accessing medicines for low income and rural populations, the affordability implications of post-LDC pricing changes, and the role of the National Essential Medicines List receives no dedicated treatment. A truly balanced reform agenda must hold industry sustainability and equitable public access as co-equal objectives, not assume that the former automatically delivers the latter.
Sadek’s article is a competent and useful industry brief that correctly identifies several urgent operational reforms. Its primary limitation is scope: it reads as an industry advocacy document rather than a holistic policy analysis. To fill its gaps, a supplementary policy paper should address R&D investment pathways, post market quality enforcement, pharmaceutical workforce development, environmental compliance, and the equity dimensions of medicine access in the post-LDC transition period. Together, these elements would constitute a reform agenda commensurate with the scale of Bangladesh’s pharmaceutical ambitions.
Reference:
